Amgen Total Stockholder Equity vs Other Current Liab Analysis
AMGN Stock | USD 305.85 4.85 1.61% |
Amgen financial indicator trend analysis is way more than just evaluating Amgen Inc prevailing accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Amgen Inc is a good investment. Please check the relationship between Amgen Total Stockholder Equity and its Other Current Liab accounts. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Amgen Inc. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in price.
Total Stockholder Equity vs Other Current Liab
Total Stockholder Equity vs Other Current Liab Correlation Analysis
The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Amgen Inc Total Stockholder Equity account and Other Current Liab. At this time, the significance of the direction appears to have significant contrarian relationship.
The correlation between Amgen's Total Stockholder Equity and Other Current Liab is -0.37. Overlapping area represents the amount of variation of Total Stockholder Equity that can explain the historical movement of Other Current Liab in the same time period over historical financial statements of Amgen Inc, assuming nothing else is changed. The correlation between historical values of Amgen's Total Stockholder Equity and Other Current Liab is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Total Stockholder Equity of Amgen Inc are associated (or correlated) with its Other Current Liab. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Other Current Liab has no effect on the direction of Total Stockholder Equity i.e., Amgen's Total Stockholder Equity and Other Current Liab go up and down completely randomly.
Correlation Coefficient | -0.37 |
Relationship Direction | Negative |
Relationship Strength | Insignificant |
Total Stockholder Equity
The total equity held by shareholders, calculated as the difference between a company's total assets and total liabilities. It represents the net value of the company owned by shareholders.Other Current Liab
Most indicators from Amgen's fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Amgen Inc current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Amgen Inc. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in price. At this time, Amgen's Selling General Administrative is very stable compared to the past year. As of the 3rd of June 2024, Tax Provision is likely to grow to about 1.4 B, while Enterprise Value Over EBITDA is likely to drop 11.29.
2021 | 2022 | 2023 | 2024 (projected) | Interest Expense | 1.2B | 1.4B | 2.9B | 3.0B | Depreciation And Amortization | 3.4B | 3.4B | 4.1B | 4.3B |
Amgen fundamental ratios Correlations
Click cells to compare fundamentals
Amgen Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Amgen fundamental ratios Accounts
2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
Total Assets | 59.7B | 62.9B | 61.2B | 65.1B | 97.2B | 102.0B | |
Short Long Term Debt Total | 29.9B | 33.0B | 33.3B | 38.9B | 64.6B | 67.8B | |
Other Current Liab | 8.5B | 10.1B | 10.7B | 12.5B | 15.4B | 16.1B | |
Total Current Liabilities | 12.8B | 11.7B | 12.2B | 15.7B | 18.4B | 19.3B | |
Total Stockholder Equity | 9.7B | 9.4B | 6.7B | 3.7B | 6.2B | 12.3B | |
Property Plant And Equipment Net | 4.9B | 4.9B | 5.2B | 5.4B | 5.9B | 3.6B | |
Net Debt | 23.9B | 26.7B | 25.3B | 31.3B | 53.7B | 56.4B | |
Retained Earnings | (21.3B) | (21.4B) | (24.6B) | (28.6B) | (26.5B) | (25.2B) | |
Cash | 6.0B | 6.3B | 8.0B | 7.6B | 10.9B | 11.5B | |
Non Current Assets Total | 41.3B | 41.8B | 41.8B | 42.9B | 66.8B | 70.2B | |
Non Currrent Assets Other | 2.2B | 5.6B | 6.5B | 5.9B | 9.6B | 10.1B | |
Cash And Short Term Investments | 8.9B | 10.6B | 8.0B | 9.3B | 10.9B | 10.5B | |
Net Receivables | 4.1B | 4.5B | 4.9B | 5.6B | 7.9B | 8.3B | |
Common Stock Shares Outstanding | 609M | 590M | 573M | 541M | 538M | 759.2M | |
Liabilities And Stockholders Equity | 59.7B | 62.9B | 61.2B | 65.1B | 97.2B | 102.0B | |
Non Current Liabilities Total | 37.2B | 41.9B | 42.3B | 45.8B | 72.5B | 76.2B | |
Other Current Assets | 1.9B | 2.1B | 2.4B | 2.4B | 281M | 267.0M | |
Other Stockholder Equity | (528M) | (985M) | 18.2B | 21.7B | 25.0B | 26.2B | |
Total Liab | 50.0B | 53.5B | 54.5B | 61.5B | 90.9B | 95.5B | |
Property Plant And Equipment Gross | 4.9B | 4.9B | 14.0B | 14.7B | 15.7B | 16.5B | |
Total Current Assets | 18.4B | 21.1B | 19.4B | 22.2B | 30.3B | 15.2B | |
Accumulated Other Comprehensive Income | (528M) | (985M) | (796M) | (231M) | (289M) | (274.6M) | |
Short Term Debt | 3.0B | 91M | 87M | 1.6B | 1.4B | 1.0B | |
Inventory | 3.6B | 3.9B | 4.1B | 4.9B | 9.5B | 10.0B | |
Accounts Payable | 1.4B | 1.4B | 1.4B | 1.6B | 1.6B | 1.7B | |
Common Stock Total Equity | 31.5B | 31.8B | 32.1B | 32.5B | 37.4B | 27.1B | |
Short Term Investments | 2.9B | 4.4B | 48M | 1.7B | 10.9B | 12.2B | |
Capital Stock | 31.5B | 31.8B | 32.1B | 32.5B | 33.1B | 27.5B | |
Common Stock | 31.5B | 31.8B | 32.1B | 32.5B | 33.1B | 27.5B | |
Other Assets | 955M | 1.3B | 6.5B | 2.2B | 2.5B | 1.4B | |
Long Term Debt | 27.0B | 32.9B | 33.2B | 37.4B | 63.2B | 66.3B | |
Property Plant Equipment | 4.9B | 4.9B | 5.2B | 5.4B | 6.2B | 5.3B | |
Good Will | 14.7B | 14.7B | 14.9B | 15.5B | 18.6B | 14.4B | |
Intangible Assets | 19.4B | 16.6B | 15.2B | 16.1B | 32.6B | 34.3B | |
Other Liab | 9.9B | 9.0B | 9.1B | 7.9B | 9.1B | 5.1B | |
Net Tangible Assets | (24.4B) | (21.9B) | (23.4B) | (27.9B) | (25.2B) | (23.9B) | |
Retained Earnings Total Equity | (21.3B) | (21.4B) | (24.6B) | (28.6B) | (25.8B) | (24.5B) | |
Long Term Debt Total | 27.0B | 32.9B | 33.2B | 37.4B | 43.0B | 29.9B | |
Non Current Liabilities Other | 9.6B | 9.0B | 2.5B | 2.7B | 2.3B | 2.2B |
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Trending Equities to better understand how to build diversified portfolios, which includes a position in Amgen Inc. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in price. Note that the Amgen Inc information on this page should be used as a complementary analysis to other Amgen's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Financial Widgets module to easily integrated Macroaxis content with over 30 different plug-and-play financial widgets.
Complementary Tools for Amgen Stock analysis
When running Amgen's price analysis, check to measure Amgen's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Amgen is operating at the current time. Most of Amgen's value examination focuses on studying past and present price action to predict the probability of Amgen's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Amgen's price. Additionally, you may evaluate how the addition of Amgen to your portfolios can decrease your overall portfolio volatility.
Portfolio Volatility Check portfolio volatility and analyze historical return density to properly model market risk | |
Idea Analyzer Analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas | |
Equity Analysis Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities | |
Stock Tickers Use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites | |
Content Syndication Quickly integrate customizable finance content to your own investment portal | |
Portfolio Optimization Compute new portfolio that will generate highest expected return given your specified tolerance for risk | |
Price Transformation Use Price Transformation models to analyze the depth of different equity instruments across global markets | |
Fundamentals Comparison Compare fundamentals across multiple equities to find investing opportunities | |
Transaction History View history of all your transactions and understand their impact on performance |
Is Amgen's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Amgen. If investors know Amgen will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Amgen listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth (0.52) | Dividend Share 8.64 | Earnings Share 7 | Revenue Per Share 55.148 | Quarterly Revenue Growth 0.22 |
The market value of Amgen Inc is measured differently than its book value, which is the value of Amgen that is recorded on the company's balance sheet. Investors also form their own opinion of Amgen's value that differs from its market value or its book value, called intrinsic value, which is Amgen's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Amgen's market value can be influenced by many factors that don't directly affect Amgen's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Amgen's value and its price as these two are different measures arrived at by different means. Investors typically determine if Amgen is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Amgen's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.